Review
Medicine, General & Internal
Sophia Liff Maibom, Ulla Nordstrom Joensen, Alicia Martin Poulsen, Henrik Kehlet, Klaus Brasso, Martin Andreas Roder
Summary: A systematic review was conducted to study short-term morbidity and mortality following radical cystectomy for bladder cancer, revealing high rates of complications and mortality. Age and comorbidity were identified as the best predictors for complications following RC. Randomized studies are needed to address interventions to reduce morbidity and mortality.
Article
Multidisciplinary Sciences
Lianghui Zhao, Lili Jing, Jie Li, Xianli Du
Summary: Long-term orthokeratology treatment in myopic children leads to a small but statistically significant increase in corneal densitometry values. The onset of these changes is related to the fitting mode during the first year. After discontinuation of treatment for one month, corneal densitometry values do not decrease significantly.
Article
Immunology
Xianjing Chu, Lishui Niu, Gang Xiao, Haiqin Peng, Fuxing Deng, Zhiyuan Liu, Honghua Wu, Lei Yang, Zhuguilong Tan, Zhanzhan Li, Rongrong Zhou
Summary: Immunotherapy has shown superior efficacy compared to non-immunotherapy treatments for NSCLC patients with BM. Dual ICI combined CT and ICI combined CT seem to be the optimal choices. Concurrent administration of SRS and ICI leads to better outcomes than non-concurrent or non-SRS. There is no significant difference in PFS and OS among different types of ICIs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Destin Groff, Ashley Sun, Anna E. Ssentongo, Djibril M. Ba, Nicholas Parsons, Govinda R. Poudel, Alain Lekoubou, John S. Oh, Jessica E. Ericson, Paddy Ssentongo, Vernon M. Chinchilli
Summary: This systematic review found that more than half of COVID-19 survivors experienced PASC 6 months after recovery, with the most common effects being functional mobility impairments, pulmonary abnormalities, and mental health disorders.
Review
Biochemistry & Molecular Biology
Enrico Capuzzi, Alice Caldiroli, Martina Capellazzi, Ilaria Tagliabue, Matteo Marcatili, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli, Antonios Dakanalis
Summary: For long-term efficacy, esketamine treatment for treatment-resistant depression shows some stability in preventing relapse, but there is debate regarding its long-term antidepressant effects after discontinuation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
T. B. van der Houwen, B. Humer, T. O. Missotten, A. A. H. J. Thiadens, P. M. van Hagen, J. A. M. van Laar
Summary: The long-term efficacy of adalimumab in treating Behcet's disease was found to be significant and safe, with a low incidence of serious adverse events, according to a retrospective cohort study.
CLINICAL IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Xiaohang Chen, Bi Yang, Xue Wang, Wei Ma, Longqian Liu
Summary: This study investigated the changes in biometric parameters among Chinese adolescents over an extended period of wearing orthokeratology lenses, as well as the subsequent changes after a one-month cessation of lens usage. The results showed that the axial length increased significantly after 36 months of lens wearing and did not fully recover after one month of lens cessation. However, the intraocular pressure and anterior chamber depth returned to their initial levels.
ANNALS OF MEDICINE
(2023)
Review
Medicine, General & Internal
Hua-Hua Yang, Yi Huang, Xu-Chun Zhou, Ruo-Nan Wang
Summary: The study found that there was no significant difference between ADA and IFX in inducing response, maintaining response, and loss of response in the treatment of Crohn's disease, but ADA had fewer overall adverse events than IFX.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Review
Gastroenterology & Hepatology
L. M. Janssen, R. H. Creemers, A. A. van Bodegraven, M. J. Pierik
Summary: This systematic review examines the outcomes used to assess long-term efficacy in clinical trials for Crohn's disease. The study found that none of the published clinical trials reported sustained remission on all treatment targets. Most studies used cross-sectional measures or multiple measurements over time, resulting in a lack of information regarding sustained corticosteroid-free remission for this relapsing-remitting chronic disease.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Pharmacology & Pharmacy
Eugenia Santacana Juncosa, Lorena Rodriguez-Alonso, Ariadna Padulles Zamora, Jordi Guardiola, Francisco Rodriguez-Moranta, Katja Serra Nilsson, Jordi Bas Minguet, Francisco Morandeira Rego, Helena Colom Codina, Nuria Padulles Zamora
Summary: Therapeutic drug monitoring of infliximab combined with Bayesian forecasting methodology can effectively improve clinical responses in patients with inflammatory bowel disease. Optimized dosing of infliximab through this approach helps increase remission rates and overall treatment efficacy for these patients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Review
Pediatrics
Joshuan J. Barboza, Leonardo Albitres-Flores, Marco Rivera-Meza, Jaime Rodriguez-Huapaya, Jose Caballero-Alvarado, Vinay Pasupuleti, Adrian V. Hernandez
Summary: The study found that umbilical cord milking (UCM) did not decrease overall mortality, intraventricular hemorrhage, or patent ductus arteriosus compared to immediate or delayed cord clamping, but it reduced the need for blood transfusion and improved mean blood pressure, hemoglobin, and ferritin levels.
PEDIATRIC RESEARCH
(2021)
Review
Environmental Sciences
Juan Victor Ariel Franco, Luis Ignacio Garegnani, Gisela Viviana Oltra, Maria-Inti Metzendorf, Leonel Fabrizio Trivisonno, Nadia Sgarbossa, Denise Ducks, Katharina Heldt, Rebekka Mumm, Benjamin Barnes, Christa Scheidt-Nave
Summary: This study aimed to describe the findings of studies assessing the global well-being and recovery outcomes in children and adolescents following COVID-19. The study found that COVID-19 may have a greater impact on the quality of life and symptom duration in younger children and those with more severe disease, while the impact on adolescents is smaller. The degree of impact on daily activities and school attendance following COVID-19 is uncertain and heterogeneous. There is also a wide range of estimates on the persistence of symptoms following COVID-19, and more high-quality studies are needed to determine the proportion of persistent symptoms. Data on resource use and rehabilitation needs are limited.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Review
Public, Environmental & Occupational Health
Joshua Jeong, Helen O. Pitchik, Guenther Fink
Summary: Parenting interventions during early childhood have shown immediate benefits on child development outcomes, but these effects tend to fade over time. Longitudinal studies are needed to understand the long-term effectiveness of such interventions and improve future intervention designs for sustained benefits.
Review
Behavioral Sciences
Felipe Figueredo Savi, Alexandre de Oliveira, Gabriela Ferreira de Medeiros, Fernando Augusto Bozza, Monique Michels, Tarek Sharshar, Felipe Dal-Pizzol, Cristiane Ritter
Summary: This review explored behavioral tools and tests used to evaluate cognitive dysfunction in different animal models of sepsis. Both CLP and LPS models were effective in inducing short-and long-term behavioral impairment.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2021)
Review
Immunology
Roberto Caporali, Yannick Allanore, Rieke Alten, Bernard Combe, Patrick Durez, Florenzo Iannone, Mike T. Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park, Dae Hyun Yoo
Summary: The study found that CT-P13 SC has more advantages compared to infliximab in treating patients with RA, demonstrating better efficacy and safety. Comparison with historical data also showed that CT-P13 SC has certain advantages over adalimumab/etanercept in terms of safety and efficacy.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2021)
Letter
Gastroenterology & Hepatology
Joshua Quan, Christopher Ma, Remo Panaccione, Lindsay Hracs, Nastaran Sharifi, Michelle Herauf, Ante Makovinovic, Stephanie Coward, Joseph W. Windsor, Lea Caplan, Richard J. M. Ingram, Jamil N. Kanji, Graham Tipples, Jessalyn K. Holodinsky, Charles N. Bernstein, Douglas J. Mahoney, Sasha Bernatsky, Eric Benchimol, Gilaad G. Kaplan
Article
Gastroenterology & Hepatology
Jocelyn Jeong, Thomas D. Walters, Hien Q. Huynh, Sally Lawrence, David R. Mack, Colette Deslandres, Anthony Otley, Wael El-Matary, Mary Sherlock, Anne M. Griffiths, Eytan Wine, Kevan Jacobson, Peter Church, Matthew W. Carroll, Eric Benchimol, Herbert Brill, Jeff Critch, Kevin Bax, Prevost Jantchou, Mohsin Rashid, Gilaad G. Kaplan, Cynthia H. Seow, Kerri Novak, Jennifer C. deBruyn
Summary: This study examines the ancestral and phenotypic variation of Canadian children newly diagnosed with inflammatory bowel disease. It identifies differences between children of European and non-European descent in phenotypes of inflammatory bowel disease, disease location and behavior, family history, and immigrant status.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Haim Leibovitzh, Sun-Ho Lee, Juan Antonio Raygoza Garay, Osvaldo Espin-Garcia, Mingyue Xue, Anna Neustaeter, Ashleigh Goethel, Hien Q. Huynh, Anne M. Griffiths, Dan Turner, Karen L. Madsen, Paul Moayyedi, A. Hillary Steinhart, Mark S. Silverberg, Colette Deslandres, Alain Bitton, David R. Mack, Kevan Jacobson, Maria Cino, Guy Aumais, Charles N. Bernstein, Remo Panaccione, Batia Weiss, Jonas Halfvarson, Wei Xu, Williams Turpin, Kenneth Croitoru
Summary: This study identified serum proteomic signatures associated with future development of Crohn's disease (CD), reflecting potential early biological processes of immune and barrier dysfunction.
Article
Gastroenterology & Hepatology
Michael J. Buie, Stephanie Coward, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Lindsay Hracs, Christopher Ma, Remo Panaccione, Eric Benchimol, Charles N. Bernstein, Alain Bitton, Anthony R. Otley, Jennifer L. Jones, Sanjay K. Murthy, M. Ellen Kuenzig, Juan-Nicolas Pena-Sanchez, Laura E. Targownik, Harminder Singh, Antonio Avina-Zubieta, Gilaad G. Kaplan
Summary: Recent advances in IBD management have led to a decrease in hospitalization rates for IBD-related and non-IBD-related causes. The study observed a decline in all-cause hospitalization rates as well.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Florence-Damilola Odufalu, Marla C. Dubinsky, Laurent Peyrin-Biroulet, Karoliina Ylanne, Allyson Sipes, Joseph C. Cappelleri, Leo J. Russo, Michelle Segovia, Sean Gardiner, Edward P. Johnson, Amy Mulvey, Remo Panaccione
Summary: This study investigated the impact of patient demographics and psychological comorbidities on disease management and health care experience in patients with ulcerative colitis, highlighting the need for better understanding and improvement of patient care.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Thomas M. Goodsall, Alice S. Day, Jane M. Andrews, Andrew Ruszkiewicz, Christopher Ma, Robert Bryant
Summary: This cohort study compared the histological and intestinal ultrasound activity of ulcerative colitis in patients undergoing endoscopy. It found that a composite of intestinal ultrasound and fecal calprotectin could accurately predict histological activity in ulcerative colitis, providing a noninvasive marker for disease activity.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Silvio Danese, Jacinda Tran, Geert D'Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou, Dapo Ilo, Xuan Yao, Yuri Sanchez Gonzalez, Remo Panaccione
Summary: This post hoc analysis evaluated the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in patients with ulcerative colitis. The results showed that upadacitinib induction treatment significantly reduced abdominal pain and bowel urgency, and also improved fatigue symptoms.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Johan Burisch, Ekaterina Safroneeva, Raphael Laoun, Christopher Ma
Summary: Although UC and CD share common pathways and treatments, CD patients are more likely to undergo surgery than UC patients. Early treatment in CD can modify the disease's natural history, but there is limited evidence supporting the utility of early escalation to advanced therapies in UC. More data is needed to determine the meaningfulness of different outcomes in UC and to analyze different populations of UC patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Christopher Ma, Theshani Amalka De Silva, Lotus Alphonsus, Leonardo Guizzetti, Eileen Crowley, Siddharth Singh, Vipul Jairath
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Silvio Danese, Remo Panaccione, Maria T. Abreu, David T. Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C. Wolf, Michael Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T. Osterman, Hsiuanlin Wu, James B. Canavan, Annkatrin Petersen, Jean-Frederic Colombel, Miguel Regueiro
Summary: This interim analysis examines the efficacy and safety of ozanimod treatment in patients with ulcerative colitis over a period of approximately 3 years. The results show that a high percentage of patients maintain clinical and mucosal efficacy during the treatment. No new safety concerns arise from long-term use of ozanimod.
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
R. Panaccione, I. Dotan, M. Ferrante, S. Danese, P. Bossuyt, K. Kligys, E. Neimark, J. Zambrano, X. Liao, G. D'Haens
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
J. Panes, R. Panaccione, B. Sands, C. Gasink, C. Marano, T. Ma, T. Hoops
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire
Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Correction
Gastroenterology & Hepatology
William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes
JOURNAL OF CROHNS & COLITIS
(2023)